0000886163-18-000132.txt : 20180905
0000886163-18-000132.hdr.sgml : 20180905
20180905200013
ACCESSION NUMBER: 0000886163-18-000132
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180904
FILED AS OF DATE: 20180905
DATE AS OF CHANGE: 20180905
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Berkman Charles S
CENTRAL INDEX KEY: 0001392266
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33093
FILM NUMBER: 181056470
MAIL ADDRESS:
STREET 1: 11085 NORTH TORREY PINES ROAD
STREET 2: SUITE 300
CITY: LA JOLLA
STATE: CA
ZIP: 92037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000886163
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770160744
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-550-7500
MAIL ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2018-09-04
0
0000886163
LIGAND PHARMACEUTICALS INC
LGND
0001392266
Berkman Charles S
3911 SORRENTO VALLEY BOULEVARD, STE 110
SAN DIEGO
CA
92121
0
1
0
0
SVP, Gen. Counsel & Secretary
Common Stock
2018-09-04
4
M
0
469
21.92
A
28232
D
Common Stock
2018-09-04
4
M
0
5985
74.42
A
34217
D
Common Stock
2018-09-04
4
M
0
7077
56.26
A
41294
D
Common Stock
2018-09-04
4
M
0
5886
85.79
A
47180
D
Common Stock
2018-09-04
4
S
0
19417
254.9861
D
27763
D
Employee Stock Option (right to buy)
56.26
2018-09-04
2018-09-04
4
M
0
7077
0.0
D
2025-02-10
Common Stock
7077
3292
D
Employee Stock Option (right to buy)
74.42
2018-09-04
2018-09-04
4
M
0
5985
0.0
D
2024-02-12
Common Stock
5985
1931
D
Employee Stock Option (right to buy)
85.79
2018-09-04
2018-09-04
4
M
0
5886
0.0
D
2026-02-11
Common Stock
5886
4577
D
Non-Qualified Stock Option (right to buy)
21.92
2018-09-04
2018-09-04
4
M
0
469
0.0
D
2023-02-15
Common Stock
469
0
D
The sale(s) reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 29, 2018, in accordance with Rule 10b5-1.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $252.85 to $256.59, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/10/15.
Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/12/14.
Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/11/16.
Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 02/15/13.
Charles S. Berkman
2018-09-05